cropped-REPRIEVE-Logo-Web4.pngcropped-REPRIEVE-Logo-Web4.pngcropped-REPRIEVE-Logo-Web4.pngcropped-REPRIEVE-Logo-Web4.png
  • About REPRIEVE
    • Spread the Word about REPRIEVE!
    • REPRIEVE Insights Newsletter
    • Publications and Plain Language Summaries
    • Our Story
    • In the News
    • Study FAQ
  • Meet Our Team
    • Clinical Coordinating Center (CCC)
    • Data Coordinating Center (DCC)
    • Community Scientific Subcommittee (CSS)
    • REPRIEVE Community Advisory Board (CAB)
    • National Institutes of Health
  • For Participants
    • REPRIEVE 2023 Community Forums
    • Meet REPRIEVE Participants
  • Contact Us
✕

Review Articles and Related Publications

September 11, 2024

What have we learned from the REPRIEVE trial and where do we go from here?

Cardiovascular disease (CVD) rates are increased 50%-100% among people with HIV. The mechanisms of CVD in people with HIV include traditional risk factors such as smoking, […]
Do you like it?
Read more
November 14, 2022

Pathophysiology and management of cardiovascular disease in patients with HIV

Results from several studies have suggested that people with HIV have an increased risk of cardiovascular disease, especially coronary heart disease, compared with people not infected […]
Do you like it?
Read more
November 14, 2022

Inflammation, immune activation, and cardiovascular disease in HIV

Cardiovascular disease is one of the leading causes of morbidity and mortality in people living with HIV. Several epidemiological studies have shown an increased risk of […]
Do you like it?
Read more
November 14, 2022

Epidemiology of ischemic heart disease in HIV

Purpose of review The purpose of this review is to summarize and synthesize recent data on the risk of ischemic heart disease (IHD) in HIV-infected individuals. […]
Do you like it?
Read more
November 14, 2022

HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial

HIV infection is associated with increased cardiovascular disease (CVD), and increased rates of myocardial infarction and stroke have been observed in HIV-infected individuals. After traditional risk […]
Do you like it?
Read more
November 14, 2022

Increased prevalence of clonal hematopoiesis of indeterminate potential amongst people living with HIV

People living with human immunodeficiency virus (PLWH) have significantly increased risk for cardiovascular disease in part due to inflammation and immune dysregulation. Clonal hematopoiesis of indeterminate […]
Do you like it?
Read more
November 14, 2022

Benefits and risks of statin therapy in the HIV infected population

Purpose of review HIV-infected patients face an increased risk for cardiovascular disease (CVD), estimated at 1.5 to 2-fold as compared to HIV uninfected persons. This review […]
Do you like it?
Read more
November 14, 2022

Statins for primary cardiovascular disease prevention among people with HIV: emergent directions

Purpose of review While people with HIV (PWH) are living longer due to advances in antiretroviral therapy, recent data have demonstrated an increased risk of cardiovascular […]
Do you like it?
Read more

Search

✕
 

Recent News

  • ACTG Presents Important Findings from REPRIEVE at CROI 2025
    March 13, 2025
  • ACTG Presents Study at CROI Demonstrating Increased Risk of Obesity and Cardiometabolic Disease After Switch to Integrase Inhibitor-Containing Regimen
    March 13, 2025
©2019 | This website, and any related materials applies only to REPRIEVE A5332.